Dengue is a mosquito-borne viral disease which is transmitted primarily by the Aedes aegypti mosquito. There are four distinct, but closely related, serotypes of the virus that cause dengue. Dengue symptoms are flu-like marked by fever, severe headaches and extreme joint and muscle pain. There is no vaccine or treatment for the virus, which can cause death, especially among infants. Infected patients are primarily treated with fluids and drugs to reduce fever. There are an estimated 100 million cases of dengue and 25,000 deaths annually. Dengue is endemic in South East Asia and Latin American countries and there are concerns it could become endemic in Europe and the United States, according to the U.S. Centers for Disease Control (CDC).
Transmission has increased predominantly in urban and semi-urban areas and has become a major international public health concern. Half the world’s population is now at risk for dengue, according to the World Health Organization (WHO). Spread of the disease is blamed in part on international travel as well as growing international trade, which can carry infected mosquitoes around the world in cargo.
VaxInnate has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund the development of a vaccine for the prevention of dengue. The grant provides funding of $2.2 million over a period of three years to develop a recombinant tetravalent dengue vaccine using our proprietary technology.